（来源：中国医药报） 转自：中国医药报 □ 王志钢 双黄连口服液主要成分为金银 花、黄 芩、连 翘，具有疏风解表、清热解毒的功效，适用于外感风热所 致的感冒，症见发热、咳嗽、咽痛。 冬季，天气寒冷，人们易受风寒刺激发生感冒。治疗感冒的中成药种类较多，每种药物的成分、适应证 和禁忌证各不相同。盲目选用治疗感冒中成药可能延误病情，增加不良反应发生风险。因此，正确选用 中成药是保障疗效与用药安全的关键。 按照人体感受风邪兼夹不同病邪或不同体质感邪来划分，感冒可分为风寒感冒、风热感冒、暑湿感冒和 体虚感冒；按照病证虚实来划分，风寒感冒、风热感冒、暑湿感冒为实证感冒，体虚感冒为虚证感冒。 除此之外，还有时行感冒，相当于西医的流行性感冒。 风寒感冒 风寒感冒一般发生于寒冷季节，通常由吹风、受凉等因素引起，症见恶寒重、发热轻、无汗、头痛、肢 体酸痛、鼻塞、流清涕、咽痒、咳嗽、痰白稀薄等，治疗应以辛温解表、宣肺散寒为主。临床常用以下 中成药治疗风寒感冒。 感冒清热颗粒主要成分为荆芥穗、薄荷、防风、柴胡、紫苏叶等，具有疏风散寒、解表清热的功效，用 于治疗风寒感冒引起的头痛发热、恶寒身痛、鼻流清涕、咳嗽咽干。患者服药后可喝些热粥 ...

Core Viewpoint - The company Jinghua Pharmaceutical (002349.SZ) does not currently produce any drugs specifically for the treatment of respiratory syncytial virus (RSV) [1] Product Overview - The company's product Qingzhai Hu Yin Granules is used for symptoms such as fever, chills, headache, nasal congestion, sneezing, throat itching, cough, and limb soreness, suitable for initial stages of influenza and mild upper respiratory infections [1] - The product Wang's Baochi Pill is effective for pediatric conditions like milk stagnation, phlegm-induced seizures, cough with phlegm, reduced milk intake, diarrhea with fever, seasonal colds, as well as for adults with gastrointestinal issues [1] - The product Jin Qiao Mai Pian has functions of clearing heat and detoxifying, promoting pus discharge, and relieving cough and asthma, mainly used for acute lung abscess, acute and chronic bronchitis, asthma, and bacterial dysentery [1] - The product Ji Desheng Snake Medicine Tablets has effects of clearing heat and detoxifying, reducing swelling and relieving pain, treating snake and insect bites, and has unique efficacy against viral infections, bacterial infections, and immune deficiencies [1]

Core Viewpoint - The company demonstrates resilience and growth potential in a complex industry environment, with steady revenue growth, significant cash flow improvement, and enhanced competitiveness of core products, alongside advancing internationalization and R&D innovation [1]. Financial Performance - For the first half of 2025, the company achieved revenue of 731 million yuan, a year-on-year increase of 1.54%; net profit attributable to shareholders was 131 million yuan, with a net profit of 127 million yuan after excluding non-recurring gains and losses, indicating solid profitability in core operations [2]. - The net cash flow from operating activities surged by 31.87% to 128 million yuan, reflecting improved operational quality and enhanced capital management efficiency [2]. Core Product Strength - Sales revenue from traditional Chinese medicine preparations grew by 12.45% year-on-year to 287 million yuan, serving as a key support for performance [3]. - Key products such as "Wang's Baochi Pill," "Jide Sheng Snake Medicine Tablets," and "Zheng Chai Hu Drink Granules" continue to gain clinical and market recognition due to their unique efficacy and strong brand heritage [3]. - "Wang's Baochi Pill" was included in the "International Clinical Practice Guidelines for Functional Dyspepsia in Traditional Chinese Medicine (2025 Edition)," enhancing its international influence [3]. International Expansion - The company actively expanded its overseas market, achieving self-operated export sales of 11.3 million USD, a year-on-year increase of 16% [4]. - Several raw material drug varieties have received FDA and CEP certifications, gaining international quality recognition [4]. R&D and Capacity Development - The company places high importance on R&D investment, collaborating with universities on various pharmacological and clinical research projects [5]. - The approval of new indications for "Diphenhydramine Hydrochloride Tablets" by the National Medical Products Administration further enriches the product line [5]. - Projects for traditional Chinese medicine preparation production bases, GMP certification upgrades, and energy-saving renovations are progressing steadily, laying the foundation for future capacity release and quality upgrades [5]. Cost Reduction and Efficiency Improvement - Through process optimization, intelligent equipment upgrades, and procurement cost control, the company achieved cost reductions exceeding 5 million yuan in the first half of the year [6]. - A successful stock incentive plan was implemented in May, granting 15.494 million restricted shares to 105 core employees, effectively motivating the team for long-term development [6]. Social Responsibility - The company continues to promote the construction of GAP bases for Chinese medicinal materials in Gansu Longxi, adopting a "leading enterprise + base + cooperative" model to boost local farmers' income [7]. - During the reporting period, the company procured local medicinal materials worth 30.946 million yuan, creating over 70 jobs, showcasing the responsibility and commitment of state-owned enterprises [7].